Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMPD2 | O60906 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4564576 | 1.00 | ALDH1A1 (0.41) | ALDH1A1GLATSHRSLC6A2SLC6A4 | |
| SCHEMBL27820012 | 1.00 | ALDH1A1 (0.41) | ALDH1A1GLATSHRSLC6A2SLC6A4 | |
| SCHEMBL430659 | 0.85 | ALDH1A1 (0.46) | ALDH1A1GLATSHRSLC6A2SLC6A4 | |
| SCHEMBL430660 | 0.85 | ALDH1A1 (0.46) | ALDH1A1GLATSHRSLC6A2SLC6A4 | |
| SCHEMBL28130586 | 0.83 | SLC6A2 (0.51) | ALDH1A1GLATSHRSLC6A2SLC6A4 | |
| SCHEMBL27761276 | 0.83 | ALDH1A1 (0.45) | ALDH1A1GLATSHRSLC6A2SLC6A4 | |
| SCHEMBL11042753 | 0.83 | CPA3 (0.42) | ALDH1A1GLATSHRSLC6A2SLC6A4 | |
| SCHEMBL4964528 | 0.81 | CYP1A2 (0.50) | ALDH1A1KMT2AMEN1CYP2C9CYP2C19 | |
| SCHEMBL3260043 | 0.81 | ALDH1A1 (0.39) | ALDH1A1GLATSHRKMT2ASMN1; SMN2 | |
| SCHEMBL3342746 | 0.81 | NR4A2 (0.48) | ALDH1A1GLATSHRSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078364-B2 | Curable composition and use of same | OSAKA GAS CHEMICALS CO., LTD. (JP) | 2021-08-03 | — | — | US | disclosed |
| US-20210087394-A1 | CURABLE COMPOSITION AND USE OF SAME | OSAKA GAS CHEMICALS CO., LTD. (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3674375-A1 | CURABLE COMPOSITION AND USE OF SAME | Osaka Gas Chemicals Co., Ltd. (JP) | 2020-07-01 | — | — | EP | disclosed |
| EP-2809315-A1 | IMPROVING POSTURAL STABILITY ADMINISTERING DROXIDOPA | Lundbeck Na Ltd (US) | 2014-12-10 | — | — | EP | disclosed |
| EP-2134335-B1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF FIBROMYALGIA | CHELSEA THERAPEUTICS INC (US) | 2014-04-23 | — | — | EP | disclosed |
| WO-2013116325-A1 | IMPROVING POSTURAL STABILITY ADMINISTERING DROXIDOPA | CHELSEA THERAPEUTICS, INC. (US) | 2013-08-08 | — | — | WO | disclosed |
| US-20130197090-A1 | POSTURAL STABILITY AND INCIDENT FUNCTIONS IN PATIENTS | CHELSEA THERAPEUTICS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130143868-A1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF MOOD DISORDERS, SLEEP DISORDERS, OR ATTENTION DEFICIT DISORDERS | CHELSEA THERAPEUTICS, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130116286-A1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF NEURALLY MEDIATED HYPOTENSION | CHELSEA THERAPEUTICS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-8383681-B2 | Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders or attention deficit disorders | CHELSEA THERAPEUTICS, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| WO-2008112773-A2 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF NEURALLY MEDIATED HYPOTENSION | CHELSEA THERAPEUTICS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20080227830-A1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF NEURALLY MEDIATED HYPOTENSION | CHELSEA THERAPEUTICS, INC. | 2008-09-18 | — | — | US | disclosed |
| US-20080221170-A1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF FIBROMYALGIA | CHELSEA THERAPEUTICS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080057228-A1 | Anti-glare film and liquid crystal display apparatus | SHARP CORPORATION | 2008-03-06 | — | — | US | disclosed |
| EP-0744955-A4 | CYCLIC HEPTAPEPTIDE ANTI-INFLAMMATORY AGENT | UNIV CALIFORNIA (US) | 1998-12-16 | — | — | EP | disclosed |
| EP-0744955-A1 | CYCLIC HEPTAPEPTIDE ANTI-INFLAMMATORY AGENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-12-04 | — | — | EP | disclosed |
| WO-1995022339-A1 | CYCLIC HEPTAPEPTIDE ANTI-INFLAMMATORY AGENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-08-24 | — | — | WO | disclosed |
| US-5346828-A | Stereoisomeric enrichment of 2-amino-3-hydroxy-3-phenylpropionic acids using d-threonine aldolase | CELGENE CORPORATION (US) | 1994-09-13 | — | — | US | disclosed |
| EP-0218440-A3 | N-METHYLPHENYLSERINE ALKYL ESTER DERIVATIVES AND USES THEREOF | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1988-01-13 | — | — | EP | disclosed |
| EP-0218440-A2 | N-Methylphenylserine alkyl ester derivatives and uses thereof | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1987-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130197090-A1 | POSTURAL STABILITY AND INCIDENT FUNCTIONS IN PATIENTS | PARK7, SNCA, COMT | ALDH1A1 2053/4885GLA 2722/4885TSHR 1294/4885 |
| US-20080227830-A1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF NEURALLY MEDIATED HYPOTENSION | ADRA1D, QDPR, ADRA2C | ALDH1A1 1814/4885GLA 3704/4885TSHR 2825/4885 |
| US-20130116286-A1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF NEURALLY MEDIATED HYPOTENSION | ADRA1D, QDPR, ADRA2C | ALDH1A1 1814/4885GLA 3704/4885TSHR 2825/4885 |
| US-20080221170-A1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF FIBROMYALGIA | HTR5A, FAAH, MTNR1B | ALDH1A1 1858/4885GLA 2264/4885TSHR 2825/4885 |
| US-20130143868-A1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF MOOD DISORDERS, SLEEP DISORDERS, OR ATTENTION DEFICIT DISORDERS | COMT, DRD2, TPH1 | ALDH1A1 401/4885GLA 2038/4885TSHR 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.